Table 2.

Relationship between MYBL2 and Ki67 expression and clinicopathological parameters in ESCC patients

	Total	MYBL2, n (%)			Ki67, n (%)
		−	+	P-value	−	+	P-value
Normal mucosa	107	73 (68.2%)	34 (31.8%)	0.007**	107 (100%)	0	–
ESCC	107	31 (29.0%)	76 (71.0%)		36 (33.6%)	71 (66.4%)
Sex
Male	66	17 (25.8%)	49 (74.2%)	0.352	23 (34.8%)	43 (65.2%)	0.738
Female	41	14 (34.1%)	27 (65.9%)		13 (31.7%)	28 (68.3%)
Age (years)
<60	43	10 (23.3%)	33 (76.7%)	0.285	16 (37.2%)	27 (62.8%)	0.522
≥60	64	21 (32.8%)	43 (67.2%)		20 (31.3%)	44 (68.8%)
Tumor size (cm)
<5	87	25 (28.7%)	62 (71.3%)	0.911	30 (34.5%)	57 (65.5%)	0.702
≥5	20	6 (30.0%)	14 (70.0%)		6 (30.0%)	14 (70.0%)
Histological differentiation
Good	13	8 (61.5%)	5 (38.5%)	0.022*	9 (69.2%)	4 (30.8%)	0.010*
Moderate	70	17 (24.3%)	53 (75.7%)		22 (31.4%)	48 (68.6%)
Poor	24	6 (25.0%)	18 (75.0%)		5 (20.8%)	19 (79.2%)
T stage
Tis–T1	22	14 (63.6%)	8 (36.4%)	<0.001***	8 (36.4%)	14 (63.6%)	0.762
T2–T3	85	17 (20.0%)	68 (80.0%)		28 (32.9%)	57 (67.1%)
Lymph-node metastasis
Present	37	5 (13.5%)	32 (86.5%)	0.010*	9 (24.3%)	28 (75.7%)	0.138
Absent	70	26 (37.1%)	44 (62.9%)		27 (38.6%)	43 (61.4%)
TNM stage
0–I	26	16 (61.5%)	10 (38.5%)	<0.001***	11 (42.3%)	15 (57.7%)	0.283
II–III	81	15 (18.5%)	66 (81.5%)		25 (30.9%)	56 (69.1%)
Ki67 index
Negative	36	17 (47.2%)	19 (52.8%)	0.003**	–	–	–
Positive	71	14 (19.7%)	57 (80.3%)		–	–

Notes:

^*P<0.05;

^**P<0.01;

^***P<0.001.

Abbreviation: ESCC, esophageal squamous-cell carcinoma.